Status:

TERMINATED

Allogeneic Transplantation for Patients With Acute Leukemia or Chronic Myelogenous Leukemia (CML)

Lead Sponsor:

Stanford University

Conditions:

Leukemia, Lymphocytic, Acute

Leukemia

Eligibility:

All Genders

4-55 years

Brief Summary

The purpose of the study is to evaluate the overall and disease free survival of recipients who have received G-CSF mobilized stem cells from HLA matched sibling donors.

Detailed Description

Allogeneic Peripheral Blood Stem Cell Transplantation for Patients with Acute Myelogenous Leukemia and Acute Lymphoblastic Leukemia in First Remission or Chronic Myelogenous Leukemia in First Chronic ...

Eligibility Criteria

Inclusion

  • Any patient with one of the following hematologic malignancies in whom an allogeneic stem cell transplant is warranted: Specific disease categories include:
  • acute myelogenous leukemia, 1st or 2nd remission
  • acute lymphoblastic leukemia, 1st or 2nd remission
  • chronic myelogenous leukemia, 1st or 2nd CP, accelerated phase 2. Patient age \> 1 month and \< 55 yo 3. Patients must have a genotypically HLA identical sibling 4. Patient must have adequate function as follows:
  • a. total bilirubin \<2.5 and SGOT/SGPT \<2x normal b. adequate renal function as defined by creatinine \< 1.5 or a 24 hr creatinine clearance \>50 cc/min as determined by the Cockroft-Gault formula (to be done if serum creatinine \> 1.5) c. DLCO \> 60% predicted d. radionuclide cardiac scan with ejection fraction \>45% 5. Patient must be competent to give consent.
  • Inclusion criteria (Donor):
  • HLA identical family member
  • Donor or guardian must be competent to give consent
  • Donor must have adequate veins for leukapheresis or agree to placement of central venous catheter

Exclusion

  • 2 Exclusion Criteria (Patient):
  • Evidence of active infection or active hepatitis
  • Positive serologies for HIV-1,HIV-2 or hepatitis B surface ag+
  • Previous allogeneic stem cell/bone marrow transplant
  • Pregnant or lactating patients
  • 4 Exclusion criteria (Donor):
  • Donors who for psychologic, physiologic or medical reasons are unable to tolerate PBSC harvest
  • Donors who are HIV+ or hepatitis B antigen +
  • History of allergic reaction to G-CSF
  • Female donors must be post-menopausal or have a negative pregnancy test

Key Trial Info

Start Date :

May 1 2002

Trial Type :

OBSERVATIONAL

Allocation :

ACTUAL

End Date :

April 1 2009

Estimated Enrollment :

88 Patients enrolled

Trial Details

Trial ID

NCT00185523

Start Date

May 1 2002

End Date

April 1 2009

Last Update

June 16 2016

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Stanford University School of Medicine

Stanford, California, United States, 94305